Imigran Recovery (Sumatriptan)

Sumatriptan is a selective 5‑HT1B/1D receptor agonist used in the acute treatment of migraine and related headache disorders.

• Migraine attack: provides rapid relief of headache pain and associated symptoms when taken at the onset of an attack.
• Migraine with aura: reduces the severity and duration of aura-associated migraine episodes.
• Cluster headache: can be used for the acute treatment of episodic cluster headache attacks.

• Sumatriptan selectively binds to 5‑HT1B and 5‑HT1D receptors on cranial blood vessels and trigeminal nerve terminals. Activation causes vasoconstriction of intracranial arteries and inhibits release of pro‑inflammatory neuropeptides, thereby interrupting the pain signaling cascade that underlies migraine attacks.

Common Side Effects

• Chest discomfort or tightness: mild, transient sensation often reported after dosing.
• Tingling or numbness: usually affecting the face, lips, or extremities.
• Nausea or abdominal discomfort: mild gastrointestinal upset.
• Dizziness or light‑headedness: may occur shortly after administration.
• Fatigue or drowsiness: a feeling of reduced energy.

Serious or Rare Side Effects

• Coronary vasospasm or myocardial ischemia: rare but potentially life‑threatening cardiac events.
• Serotonin syndrome: severe reaction when combined with other serotonergic agents.
• Severe allergic reaction (anaphylaxis): rapid onset of rash, swelling, or breathing difficulty.
• Hypertension or hypertensive crisis: marked increase in blood pressure.
• Stroke or transient ischemic attack: extremely rare cerebrovascular events.

Before using Imigran Recovery, consider the following precautions to ensure safe use.

• Cardiovascular assessment: evaluate history of coronary artery disease, uncontrolled hypertension, or cerebrovascular disorders.
• Concomitant serotonergic drugs: avoid use with SSRIs, SNRIs, MAO inhibitors, or other triptans due to serotonin syndrome risk.
• Pregnancy and lactation: discuss potential risks with a healthcare professional; data are limited.
• Age considerations: use with caution in elderly patients who may have comorbid conditions.
• Storage: Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Sumatriptan may interact with several medication classes; awareness helps prevent adverse events.

Major Interactions (Avoid)

• MAO inhibitors: combined use can precipitate serotonin syndrome.
• Other triptans or ergot alkaloids: increased risk of vasospasm and cardiovascular events.
• SSRIs, SNRIs, or other serotonergic agents: heightened serotonin toxicity.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise sumatriptan plasma levels.
• Certain antihypertensives (e.g., propranolol): can elevate exposure and side‑effect risk.

Moderate Interactions (Monitor Closely)

• Antihistamines: may enhance dizziness or sedation.
• Oral contraceptives: monitor for increased migraine frequency.
• NSAIDs: concurrent use may increase gastrointestinal discomfort.
• CYP2D6 inhibitors (e.g., fluoxetine): may modestly increase sumatriptan exposure.
• Diuretics: watch for blood pressure fluctuations.